rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Actinium Pharmaceuticals, Inc. (Delaware)

ATNM · NYSE American

Health CareBiotechnology

We hold no 150-day reading for ATNM yet: it needs about 200 sessions of history. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
not in the set
Weeks in an uptrend
—
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
45 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders45-4 on the quarter
New · exited8 · 12
Reported value$4.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,238,302$1.2M-17,214−1.4%
COMPASS FINANCIAL MANAGEMENT LLCnew · filed 12 Aug 2026600,230$588K+600,230
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026514,580$504K-50,020−8.9%
BlackRock, Inc.added · filed 7 Aug 2026395,896$388K+24,686+6.7%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026380,491$373K-91,109−19.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026324,945$319K-11,128−3.3%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026259,179$254K-77,989−23.1%
GAGNON SECURITIES LLCreduced · filed 5 Aug 2026182,142$178K-19,158−9.5%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026161,526$158K+1,261+0.8%
STATE STREET CORPreduced · filed 7 Aug 2026122,215$120K-4,000−3.2%
31 Mar 2023 – 30 Jun 2026
465767Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Matthew T. David Company insiderChief Financial Officer · last 14 Oct 20260 · 0
Ajit Shetty Company insiderDirector · last 2 Sep 20261 · 0
C. David Nicholson Company insiderDirector · last 2 Sep 20261 · 0
Jeffrey W. Chell Company insiderDirector · last 2 Sep 20260 · 0
June Sherie Almenoff Company insiderDirector · last 2 Sep 20260 · 0
Richard I. Steinhart Company insiderDirector · last 2 Sep 20261 · 0
Sandesh Seth Company insiderChief Executive Officer · last 2 Sep 202610 · 0
Steve O'Loughlin Company insiderChief Financial Officer · last 31 Mar 20253 · 0
Mark Stanley Berger Company insiderChief Medical Officer · last 1 Sep 20211 · 0
Dale L. Ludwig Company insiderChief Science & Tech. Officer · last 12 Aug 20201 · 0
Anil Kapur Company insiderChief Commercial Officer · last 12 Jul 20190 · 0
Nitya G. Ray Company insiderExecutive VP · last 13 Jul 20181 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-82.7%
Share count trendFY 2025 · to 30 Mar 20260.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$48.0M
Free cash flowFY 2025 · to 31 Dec 2025−$24.7M

Analyst forecasts

No analyst forecasts yet.